MedTrace Logo

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome

NCT05158439 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-02-10

No results posted yet for this study

Summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Tourette Syndrome

Conditions

  • Tourette Syndrome

Interventions

BIOLOGICAL

AlloRx

cultured allogeneic adult umbilical cord derived mesenchymal stem cells

Sponsors & Collaborators

  • The Foundation for Orthopaedics and Regenerative Medicine

    lead OTHER

Principal Investigators

  • Chadwick Prodromos, MD · The Foundation for Orthopaedics and Regenerative Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-31
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • Antigua and Barbuda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05158439 on ClinicalTrials.gov